News
![Insmed](/sites/default/files/styles/x_large/public/2024-05/insmed-building-new.jpg?itok=OnHOlIWt)
Trial readout sets up filings for Insmed bronchiectasis drug
Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis